- Home
- DOX vs ABVX Comparison
DOX vs ABVX Comparison
Compare DOX & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOX | ABVX |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.2B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOX | ABVX |
|---|---|---|
| Price | $82.34 | $118.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $97.00 | ★ $130.09 |
| AVG Volume (30 Days) | 891.4K | ★ 1.8M |
| Earning Date | 02-03-2026 | 08-11-2025 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 19.01 | N/A |
| EPS | ★ 5.05 | N/A |
| Revenue | ★ $4,532,913,000.00 | $6,231,374.00 |
| Revenue This Year | $4.57 | $6.80 |
| Revenue Next Year | $4.11 | N/A |
| P/E Ratio | $16.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $74.32 | $4.77 |
| 52 Week High | $95.41 | $148.83 |
Technical Indicators
Market Signals| Indicator | DOX | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 46.57 |
| Support Level | $82.23 | $113.64 |
| Resistance Level | $83.99 | $125.86 |
| Average True Range (ATR) | 1.42 | 7.81 |
| MACD | -0.19 | -0.55 |
| Stochastic Oscillator | 15.54 | 45.09 |
Price Performance
Historical ComparisonAbout DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.